针对AMF反应的纳米生物磁铁,用于针对莱什曼亚马逊菌 (Leishmania amazonensis) 提供安福特里辛B
Mariana Verdan1, Dirlei Nico1, Leandro Sangenito2
1Laboratório de Biologia Celular e Magnetotaxia, Centro de Ciências da Saúde, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Scientific reports
|November 14, 2025
概括
这项研究引入了一种针对皮肤莱什曼病的新型纳米颗粒疗法,在与交替磁场 (AMF) 结合时显示出有希望的生物相容性和增强的疗效. 需要进一步的体内测试来确认其作为新治疗选择的潜力.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 寄生虫学的寄生虫学
背景情况:
- 皮肤莱什曼病是一种被忽视的热带疾病,治疗选择有限,往往有毒.
- 耐药性和高成本需要新的治疗策略.
- 纳米颗粒药物递送系统提供了提高疗效和减少副作用的潜力.
研究的目的:
- 为了评估安福特素B功能化纳米生物磁铁对莱什曼亚马逊菌的体外疗效.
- 为了研究交替磁场 (AMF) 暴露对纳米配方抗莱什曼活动的协同效应.
- 评估纳米生物磁铁制剂的初步安全性和生物相容性.
主要方法:
- 纳米生物磁铁的合成由磁触性细菌和功能化与安福特里辛B.
- 在体外对Leishmania amazonensis promastigotes进行测试.
- 对HaCaT,hFB和J774.16细胞系的细胞毒性的评估.
- 在纳米粒子相互作用时对巨细胞中氧化产生的评价.
主要成果:
- 该纳米配方在体外表现出显著的抗莱什曼的活性.
- 暴露于AMF显著提高了纳米配方的治疗疗效.
- 测试的纳米配方没有表现出细胞毒性和最小的炎症反应 (氧化生产).
结论:
- 功能化的纳米生物磁铁显示出作为一种生物相容和有效的治疗剂的潜力,用于对抗Leishmania.
- 与AMF的结合提供了一个有前途的策略,用于增强皮肤莱什曼病的治疗.
- 需要进一步的体内研究来验证这些发现的临床应用.
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...